MA26960A1 - Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation - Google Patents

Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation

Info

Publication number
MA26960A1
MA26960A1 MA27158A MA27158A MA26960A1 MA 26960 A1 MA26960 A1 MA 26960A1 MA 27158 A MA27158 A MA 27158A MA 27158 A MA27158 A MA 27158A MA 26960 A1 MA26960 A1 MA 26960A1
Authority
MA
Morocco
Prior art keywords
salts
hemi
isothiazole
formula
carboxamide
Prior art date
Application number
MA27158A
Other languages
English (en)
Inventor
Thomas G Gant
Glenn Robert Williams
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26960A1 publication Critical patent/MA26960A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 28 Novembre 2000 60/253,513 Voir en annexe le titre de l'invention et le texte de l'abrégé Sels d'un isothiazole-4-carboxamide et leur utilisation comme agents anti-hyperprolifération chlorhydrate, bromhydrate, hémi-citrate, acétate, p-tosy-late, L-tartrate, hémi-succinate et mésylate d'amide d'acide 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrroli-dine-1-yle-butyl)-uréido]-isothiazole-4-carboxylique répondant à la formule suivante : formule 1. La présente invention concerne également des compositions pharmaceutiques contenant les sels consistant en chlorhydrate, bromhydrate, hémi-citrate, acétate, p-tosylate, L-tartrate, hémi-succinate et mésylate du composé de formule 1. L'invention concerne en outre des méthodes de traitement de maladies hyperprolifératives, telles que des cancers, chez des mammifères, notamment chez l'homme, en administrant les sels précités, et des procédés pour la préparation des formes cristallines des sels précités.
MA27158A 2000-11-28 2003-05-13 Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation MA26960A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28

Publications (1)

Publication Number Publication Date
MA26960A1 true MA26960A1 (fr) 2004-12-20

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27158A MA26960A1 (fr) 2000-11-28 2003-05-13 Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation

Country Status (50)

Country Link
US (1) US6831091B2 (fr)
EP (1) EP1337521B1 (fr)
JP (2) JP2004514714A (fr)
KR (2) KR20050116401A (fr)
CN (1) CN1231474C (fr)
AP (1) AP2001002358A0 (fr)
AR (1) AR031512A1 (fr)
AT (1) ATE340786T1 (fr)
AU (2) AU2002214204B2 (fr)
BG (1) BG107752A (fr)
BR (1) BR0115621A (fr)
CA (1) CA2430065C (fr)
CR (1) CR6963A (fr)
CY (1) CY1106240T1 (fr)
CZ (1) CZ20031315A3 (fr)
DE (1) DE60123461T2 (fr)
DK (1) DK1337521T3 (fr)
DO (1) DOP2001000288A (fr)
EA (1) EA005859B1 (fr)
EC (1) ECSP034628A (fr)
EE (1) EE200300247A (fr)
ES (1) ES2271086T3 (fr)
GE (1) GEP20053652B (fr)
GT (1) GT200100237A (fr)
HK (1) HK1059085A1 (fr)
HN (1) HN2001000268A (fr)
HR (1) HRP20030408A2 (fr)
HU (1) HUP0302553A3 (fr)
IL (1) IL155371A0 (fr)
IS (1) IS6788A (fr)
MA (1) MA26960A1 (fr)
MX (1) MXPA03004714A (fr)
MY (1) MY136686A (fr)
NO (1) NO325187B1 (fr)
NZ (1) NZ525788A (fr)
OA (1) OA12532A (fr)
PA (1) PA8533801A1 (fr)
PE (1) PE20020591A1 (fr)
PL (1) PL362079A1 (fr)
PT (1) PT1337521E (fr)
SI (1) SI1337521T1 (fr)
SK (1) SK5862003A3 (fr)
SV (1) SV2002000748A (fr)
TN (1) TNSN01167A1 (fr)
TW (1) TWI287542B (fr)
UA (1) UA74221C2 (fr)
UY (1) UY27039A1 (fr)
WO (1) WO2002044158A1 (fr)
YU (1) YU36403A (fr)
ZA (1) ZA200303341B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MXPA05000950A (es) * 2002-07-25 2005-05-16 Pfizer Prod Inc Derivados de isotiazol utiles como agentes anticancerosos.
AP2005003232A0 (en) * 2002-08-19 2005-03-31 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
RS52625B (en) 2003-07-23 2013-06-28 Bayer Healthcare Llc FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
JP4542550B2 (ja) * 2003-10-27 2010-09-15 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｃｒ−２アンタゴニスト塩
WO2005061519A1 (fr) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Inhibiteurs de kinase
WO2005102327A1 (fr) * 2004-04-20 2005-11-03 Pfizer Products Inc. Formes posologiques et procedes de traitement utilisant des inhibiteurs vegfr
EP1751139B1 (fr) 2004-04-30 2011-07-27 Bayer HealthCare LLC Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1812439B2 (fr) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2044043B2 (fr) 2006-06-16 2021-03-03 H. Lundbeck A/S 1-[2-(2, 4-dimethylphenylsulfanyl)-phenyl]piperazine hydrobromide comme compose presentant une activite sur la serotonine, 5-ht3 et 5-ht1a pour le traitement du deficit cognitif
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (fr) 2009-12-15 2011-06-23 Petri Salven Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations
EP2596026B1 (fr) 2010-07-23 2020-04-08 Trustees of Boston University Inhibiteurs anti-despr comme agents thérapeutiques pour l'inhibition de l'angiogenèse pathologique et de l'invasivité des cellules tumorales et pour l'imagerie moléculaire et l'administration ciblée
EP3520773A1 (fr) * 2013-03-14 2019-08-07 PanOptica, Inc. Formulations oculaires destinées à l'administration de médicament au segment postérieur de l'oeil
US9814702B2 (en) * 2014-09-17 2017-11-14 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
WO2024140850A1 (fr) * 2022-12-28 2024-07-04 苏州必扬医药科技有限公司 Inhibiteur de protéine tyrosine kinase et son utilisation médicale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
UA74221C2 (uk) 2005-11-15
GT200100237A (es) 2002-07-03
OA12532A (en) 2006-06-02
CR6963A (es) 2003-11-25
JP2004514714A (ja) 2004-05-20
PT1337521E (pt) 2006-12-29
NZ525788A (en) 2004-11-26
NO325187B1 (no) 2008-02-11
CA2430065C (fr) 2008-05-20
PL362079A1 (en) 2004-10-18
HRP20030408A2 (en) 2003-08-31
HUP0302553A2 (hu) 2003-11-28
SV2002000748A (es) 2002-12-02
AU1420402A (en) 2002-06-11
PE20020591A1 (es) 2002-07-06
ES2271086T3 (es) 2007-04-16
CZ20031315A3 (cs) 2004-04-14
GEP20053652B (en) 2005-11-10
CA2430065A1 (fr) 2002-06-06
KR20030059275A (ko) 2003-07-07
KR20050116401A (ko) 2005-12-12
BG107752A (bg) 2004-01-30
EA005859B1 (ru) 2005-06-30
NO20032388D0 (no) 2003-05-27
DK1337521T3 (da) 2007-01-29
BR0115621A (pt) 2003-09-02
SK5862003A3 (en) 2004-05-04
JP4971946B2 (ja) 2012-07-11
HK1059085A1 (en) 2004-06-18
CY1106240T1 (el) 2011-06-08
ZA200303341B (en) 2004-04-30
US20020151573A1 (en) 2002-10-17
AR031512A1 (es) 2003-09-24
IS6788A (is) 2003-04-14
ECSP034628A (es) 2003-07-25
HN2001000268A (es) 2002-01-30
EA200300424A1 (ru) 2003-10-30
EE200300247A (et) 2003-10-15
SI1337521T1 (sl) 2006-12-31
CN1476439A (zh) 2004-02-18
MY136686A (en) 2008-11-28
MXPA03004714A (es) 2003-08-19
TWI287542B (en) 2007-10-01
NO20032388L (no) 2003-07-18
HUP0302553A3 (en) 2009-03-30
DOP2001000288A (es) 2002-12-15
PA8533801A1 (es) 2002-10-31
US6831091B2 (en) 2004-12-14
AP2001002358A0 (en) 2001-12-31
UY27039A1 (es) 2002-07-31
TNSN01167A1 (fr) 2005-11-10
JP2008056692A (ja) 2008-03-13
EP1337521B1 (fr) 2006-09-27
DE60123461D1 (de) 2006-11-09
ATE340786T1 (de) 2006-10-15
AU2002214204B2 (en) 2007-05-24
WO2002044158A1 (fr) 2002-06-06
CN1231474C (zh) 2005-12-14
IL155371A0 (en) 2003-11-23
EP1337521A1 (fr) 2003-08-27
YU36403A (sh) 2006-08-17
DE60123461T2 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
MA26960A1 (fr) Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation
MA27095A1 (fr) Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
HUP0001170A2 (hu) Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények
WO2001085257A3 (fr) Compositions d'antagoniste opioide et formes de dosage
MA27385A1 (fr) Therapie combinee de maladies hyperproliferatives.
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
TR200100889T2 (tr) Disfosfonik asit içeren terkipler
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
TR199700878T1 (xx) Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar.
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
HUP0103781A2 (hu) Megismerési képesség javítására szolgáló gyógyszerkészítmények, melyek atipikus antipszihotikus szer és acetilkolinészteráz inhibitor kombinációját tartalmazzák
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
US20080299052A1 (en) Formulation to Prevent Plaque Formation
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
WO1997035574A1 (fr) Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
PT1121109E (pt) Formulacao bifasica contendo tramadol